Gyon Technologies Capital Management’s United Therapeutics UTHR Stock Holding History

Gyon Technologies Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,431	Closed	-$1.51M	–	400
2022 Q4	$1.51M	Sell	5,431 -7,994	-60%	-$2.02M	0.57%	56
2022 Q3	$2.81M	Buy	13,425 +7,908	+143%	+$1.77M	0.88%	30
2022 Q2	$1.3M	Buy	5,517 +2,472	+81%	+$503K	0.36%	89
2022 Q1	$546K	Sell	3,045 -2,196	-42%	-$418K	0.38%	90
2021 Q4	$1.13M	Sell	5,241 -11,181	-68%	-$2.19M	0.21%	140
2021 Q3	$3.03M	Buy	16,422 +4,588	+39%	+$904K	0.82%	23
2021 Q2	$2.12M	Buy	11,834 +6,383	+117%	+$1.22M	0.7%	38
2021 Q1	$912K	Sell	5,451 -25,482	-82%	-$4.25M	0.4%	62
2020 Q4	$4.7M	Buy	30,933 +23,397	+310%	+$3.07M	1.61%	3
2020 Q3	$761K	Buy	+7,536	New	+$827K	0.6%	43
2020 Q1	–	Sell	-11,186	Closed	-$985K	–	188
2019 Q4	$985K	Buy	+11,186	New	+$984K	0.65%	55

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Gyon Technologies Capital Management's UTHR Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of United Therapeutics (UTHR) in Q1 2023, closing a stake of 5,431 shares — an estimated $1.51M sold.

Gyon Technologies Capital Management first reported a position in UTHR in Q4 2019 and held it in 11 quarters. The position peaked at $4.7M in Q4 2020. 506 funds tracked by Wall St. Rank hold UTHR as of Q1 2023.

Gyon Technologies Capital Management reported no remaining United Therapeutics position as of Q1 2023 after selling out during the quarter.
Gyon Technologies Capital Management sold 5,431 United Therapeutics shares in Q1 2023, an estimated $1.51M.
Gyon Technologies Capital Management first reported a position in United Therapeutics in Q4 2019 and held it in 11 quarters.
Gyon Technologies Capital Management's United Therapeutics position peaked at $4.7M in Q4 2020.
506 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.